Opus Genetics (NASDAQ:IRD – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.
Insider and Institutional Ownership
15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Opus Genetics and ProQR Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Opus Genetics | $14.20 million | 30.38 | -$49.59 million | ($1.35) | -3.87 |
| ProQR Therapeutics | $18.36 million | 10.67 | -$47.73 million | ($0.46) | -4.04 |
ProQR Therapeutics has higher revenue and earnings than Opus Genetics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Opus Genetics and ProQR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
| ProQR Therapeutics | -223.51% | -73.83% | -35.14% |
Volatility and Risk
Opus Genetics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Opus Genetics and ProQR Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
| ProQR Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
Opus Genetics currently has a consensus price target of $11.92, indicating a potential upside of 128.41%. ProQR Therapeutics has a consensus price target of $7.50, indicating a potential upside of 303.23%. Given ProQR Therapeutics’ higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Opus Genetics.
Summary
ProQR Therapeutics beats Opus Genetics on 8 of the 15 factors compared between the two stocks.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
